TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06304909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine injection
Description: Dexmedetomidine group will receive 0.5 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine injection
Description: Dexmedetomidine group will receive 0.5 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine injection
Description: Dexmedetomidine group will receive 0.5 mcg/kg
Study: NCT06193824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: downhill treadmill walking at -10% and -20% gradient
Description: The subjects will perform downhill walking at 6 km/h for 45 min on a treadmill (-10% or -20% incline)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: downhill treadmill walking at -10% and -20% gradient
Description: The subjects will perform downhill walking at 6 km/h for 45 min on a treadmill (-10% or -20% incline)
Study: NCT05772884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Intervention
Description: Exercise duration will be gradually increased as tolerated to 50 min/session, with intensity ramping up to 65-75% HRmax by week 3. On-site exercise sessions will occur along a pre-marked walking path, and a trained staff member will walk alongside the participant to monitor their heart rate. Speed will be manipulated to achieve desired intensity and to sustain heart rate in the target zone. Heart rate will be monitored and recorded via telemetry during the on-site exercise sessions. Step cadence (i.e., steps/minute) will also be monitored and recorded during the on-site sessions and discussed with participants as a way to understand and track their speed when completing off-site walking sessions on their own.
Study: NCT06371443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sucking and swallowing exercises
Description: Sucking-swallowing exercises were applied to premature infants in the experimental group (n=41) for 14 days, once a day, 12 minutes before feeding.
Study: NCT05819099

Intervention type: DIAGNOSTIC_TEST
Intervention: An Intelligent Endoscopic Diagnosis System Developed and Verified Based on Deep Learning
Description: This study will compare the established AI model with the diagnostic results of endoscopists to evaluate the clinical auxiliary value of the model for endoscopists.

Intervention type: DIAGNOSTIC_TEST
Intervention: An Intelligent Endoscopic Diagnosis System Developed and Verified Based on Deep Learning
Description: This study will compare the established AI model with the diagnostic results of endoscopists to evaluate the clinical auxiliary value of the model for endoscopists.

Intervention type: DIAGNOSTIC_TEST
Intervention: An Intelligent Endoscopic Diagnosis System Developed and Verified Based on Deep Learning
Description: This study will compare the established AI model with the diagnostic results of endoscopists to evaluate the clinical auxiliary value of the model for endoscopists.
Study: NCT05654584

Intervention type: PROCEDURE
Intervention: laparoscopic sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy surgery will be performed by a single surgeon.
Study: NCT06337214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine Therapy Program for Reinforcing Vital Energy
Description: Comparing cancer patients who have participated in the program with those who have not, this study will examine differences in two types of quality of life questionnaires and constitution between the two groups.
Study: NCT05178576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gevokizumab
Description: 120mg IV on day 1 of every 28-day cycle for 1 year (maximum of 13 cycles)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Signatera test
Description: ctDNA monitoring at weeks 8, 12, 24, 36, 48, 60 and 72 unless disease recurrence is documented.
Study: NCT06544070

Intervention type: DEVICE
Intervention: Entia Liberty System
Description: Participants will donate finger-prick blood samples to be tested on the Entia Liberty System. The results will not be used to inform clinical decisions or affect routine clinical care in any way.

Intervention type: DEVICE
Intervention: Entia Liberty System
Description: Participants will donate finger-prick blood samples to be tested on the Entia Liberty System. The results will not be used to inform clinical decisions or affect routine clinical care in any way.

Intervention type: DEVICE
Intervention: Entia Liberty System
Description: Participants will donate finger-prick blood samples to be tested on the Entia Liberty System. The results will not be used to inform clinical decisions or affect routine clinical care in any way.
Study: NCT06030518

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnet Assisted Capsule Endoscopy
Description: Procedures will be performed in the morning after an overnight fast. Patients wear a belt containing sensors and a data recorder. The patient will be asked to drink 500-1000ml (containing 80mg simethicone; volume depending on tolerance) immediately before swallowing the capsule. Gastric examination will proceed as previously described for a robot-controlled magnetic assisted capsule endoscopy. The whole procedure is anticipated to take 30-60 minutes. The patient will be discharged from hospital on completion of gastric examination but if clinically indicated will wear the belt for small bowel capsule study for eight hours to allow small bowel examination before detaching the equipment and returning it the following day. On completion of examination, the patient will be asked to complete a questionnaire about their capsule endoscopy experience. The full study (upper GI tract and small bowel) will then be downloaded onto the computer for formal reading and reporting.
Study: NCT05499559

Intervention type: BEHAVIORAL
Intervention: Joint Academy digital treatment
Description: The Joint Academy® (www.jointacademy.com) program for people with hand OA consists of video instructed and progressively adaptable daily exercises, patient education through text lessons, possibility for a social chat group with other patients and a continuous asynchronous chat function with a personal reg. physiotherapist who supervises the patient during the full participation period. The program also contains three telephone consultations with a physiotherapist that were compulsory, one at the start, one after six weeks and one after three months.
Study: NCT05846841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Precision Treatment
Description: Precision treatment will be informed by practice guidelines (standard of care, brief advice, and guideline awareness), plus patient-specific risk feedback and personalized tobacco treatment recommendations using patients' clinical, genetic, and biomarker information.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care will be informed by practice guidelines (standard of care, brief advice, and guideline awareness).
Study: NCT04566042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy video game
Description: The intervention is a videogame which teaches the participant about acceptance and commitment therapy.
Study: NCT04874415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1RLD
Description: 1RLD=One text per day, ramped goal, loss incentive, daily goal time period

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1RLW
Description: 1RLW=One text per day, ramped goal, loss incentive, weekly goal time period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1RGD
Description: 1RGD=One text per day, ramped goal, gain incentive, daily goal time period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1RGW
Description: One text per day, ramped goal, gain incentive, weekly goal time period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2RLD
Description: Two texts per day, ramped goal, loss incentive, daily goal time period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2RLW
Description: Two texts per day, ramped goal, loss incentive, weekly goal time period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2RGD
Description: Two texts per day, ramped goal, gain incentive, daily goal time period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2RGW
Description: Two texts per day, ramped goal, gain incentive, weekly goal time period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1FLD
Description: One text per day, fixed goal, loss incentive, daily weekly goal time period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1FLW
Description: One text per day, fixed goal, loss incentive, weekly goal time period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1FGD
Description: One text per day, fixed goal, gain incentive, daily goal time period.
Study: NCT04793867

Intervention type: DIAGNOSTIC_TEST
Intervention: Xenon
Description: Subjects will be scanned on a commercial 3T whole-body MRI scanner equipped with high-performance gradient systems. Natural isotopic abundance or isotopically-enriched xenon gas (\~86% 129Xe, Linde Inc.) will be used for all studies. Subjects will be positioned supine in the scanner with a 129Xe RF coil around their chests. Using conventional proton MRI and a breath-hold acquisition, scout images will be obtained to localize the subject for subsequent 129Xe acquisitions. 129Xe images will be acquired using the same breath-hold maneuver and a pulse sequence, covering the entire lung (acquisition time \<10 s, approximately 3-mm in-plane resolution, 15-mm slice thickness or less). Additional scans (sequences) may be performed. A maximum of 4 doses of 129Xe will be given throughout the study following the calibration dose.
Study: NCT04874415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1FGW
Description: One text per day, fixed goal, gain incentive, weekly goal time period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2FLD
Description: Two texts per day, fixed goal, loss incentive, daily goal time period.
Study: NCT04874415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2FLW
Description: Two texts per day, fixed goal, loss incentive, weekly goal time period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2FGD
Description: Two texts per day, fixed goal, gain incentive, daily goal time period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2FGW
Description: Two texts per day, fixed goal, gain incentive, weekly goal time period.
Study: NCT05951218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inhibition technique
Description: Inhibition treatment consists of applying progressive pressure with the finger until resistance is felt. The patient should feel discomfort but not pain. They should stop when they consider that the trigger point has been sufficiently relaxed. All the techniques should last less than 5 minutes. Osteopaths will be trained to have a close strength during techniques. The number of Newton that will be apply will be decided during training with the investigator

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: The osteopath will perform a light touch on 4 areas for 30 seconds each time. The trigger point area must be lightly touched, followed by the upper part of the pectoralis major, the elbow and finally the anterior part of the opposite glenohumeral region.~Osteopaths will be trained to have a close strength during techniques. The number of Newton that will be apply will be decided during training with the investigator with a palpatory pressure measurement tool. A proposition of 1N will be proposed to have a very light touch, without activating the C-tactile sensors.
Study: NCT04983537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gam-COVID-Vac / Gam-COVID-Vac
Description: A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and the Gam-COVID-Vac / ChAdOx1 nCoV-19 and Gam-COVID-Vac / BBIBP-CorV groups as comparators.Comparisons will be made by contrasting the geometric means of antibody levels between each of the study arms. In addition, comparisons will be made as to whether or not the median antibody values of the alternative treatment groups are lower than: a) the 25th percentile of the median antibody value of the Gam COVID combination and b) whether the lower limit of the confidence interval of the differences in the GMC rate is lower than the conventional cut-off point of non-inferiority set at 0.67.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gam-COVID-Vac / Gam-COVID-Vac
Description: A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and the Gam-COVID-Vac / ChAdOx1 nCoV-19 and Gam-COVID-Vac / BBIBP-CorV groups as comparators.Comparisons will be made by contrasting the geometric means of antibody levels between each of the study arms. In addition, comparisons will be made as to whether or not the median antibody values of the alternative treatment groups are lower than: a) the 25th percentile of the median antibody value of the Gam COVID combination and b) whether the lower limit of the confidence interval of the differences in the GMC rate is lower than the conventional cut-off point of non-inferiority set at 0.67.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gam-COVID-Vac / Gam-COVID-Vac
Description: A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and the Gam-COVID-Vac / ChAdOx1 nCoV-19 and Gam-COVID-Vac / BBIBP-CorV groups as comparators.Comparisons will be made by contrasting the geometric means of antibody levels between each of the study arms. In addition, comparisons will be made as to whether or not the median antibody values of the alternative treatment groups are lower than: a) the 25th percentile of the median antibody value of the Gam COVID combination and b) whether the lower limit of the confidence interval of the differences in the GMC rate is lower than the conventional cut-off point of non-inferiority set at 0.67.
Study: NCT05767099

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound mesurements
Description: Compare various clinical test with ultrasound parameters to predict difficult videolaryngoscopy intubation.
Study: NCT06251193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-CBSST
Description: E-CBSST is a blended intervention that combines Cognitive Behavioral Social Skills Training and Executive Function Training.
Study: NCT06243588

Intervention type: OTHER
Intervention: clinical records review
Description: review the medical records, radiological imaging, and histological data of these patients
Study: NCT05095051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paxman Cryocompression System (PCCS)
Description: Establishing optimal temperature and pressure for limb cryocompression therapy. Healthy subjects will undergo 3 hours of limb cryocompression.~The cryocompression device used in this study consists of a control unit, and limb wraps. The control unit contains the coolant reservoir and pump to circulate the coolant and air for compression. It is able to thermoregulate (control the temperature of the circulating coolant) and offer cyclic air pressure in the wraps. The wraps cover the limbs from the elbow/knee to the fingers/toes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paxman Cryocompression System (PCCS)
Description: The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Paclitaxel will be administered as a one-hour infusion. Limb cryocompression sessions comprised of a pre-cooling period (up to one hour), continued with paclitaxel infusion and a post-cooling period (on average 30 minutes after the end of paclitaxel infusion). Overall, limb cryocompression will be administered for no longer than four hours.
Study: NCT05826275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGN-S11
Description: Small Molecule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGN-S11
Description: Small Molecule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD-1 checkpoint blockade
Study: NCT01441453

Intervention type: PROCEDURE
Group type: OTHER
Intervention: FibroScan (Transient Elastography measurement)
Description: Preoperative evaluation of liver stiffness through FibroScan
Study: NCT05599256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Model-predicted high-risk patients: weight ≤ 25 kg, ruxolitinib, 2.5mg bid po until at least day 60 post-transplant and terminated after day 100; weight \> 25 kg, ruxolitinib, 5mg bid po until at least day 60 post-transplant and terminated after day 100. If 'azoles' are taken concomitantly, ruxolitinib will start at half dose. If the patient tolerates ruxolitinib, the dose can be increased to 10mg bid po.~Model-predicted low risk: regular aGVHD prophylactic regimens.
Study: NCT05393180

Intervention type: DEVICE
Group type: OTHER
Intervention: Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF
Description: Epicardial linear lesions will be created endoscopically using the EPi-Sense®-Guided Coagulation System or EPi-Sense ST™ Coagulation System throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. Posterior and other linear lesions such as a roof lesion and mitral valve isthmus lesion will not be created during the endocardial component of the convergent procedure. This will be done endocardially using an irrigated endocardial ablation catheter.~Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi-Sense®-Guided Coagulation System or EPi-Sense ST™ Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation. .
Study: NCT06145334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Veterans Social
Description: Peer-led weekly community-based social groups (16 weeks) that are current treatment at the study site.
Study: NCT05228158

Intervention type: DRUG
Intervention: Tazemetostat
Description: Tazemetostat oral tablets.
Study: NCT06137248

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy drink
Description: Participants on this arm will consume an energy drink once daily in addition to their normal diet for 4 weeks.
Study: NCT04512716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131-I Apamistamab
Description: Patients will receive 131-I apamistamab 5-7 days prior to a single infusion of 1x10\^6 19-28z CAR T-cells/kg for those in the B-ALL cohort, or 2x10\^6 19-28z CAR T-cells/kg, for those in the DLBCL. 131-I apamistamab may be administered inpatient or outpatient at the discretion and judgment of the treating investigators.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T-cell
Description: 19-28z CAR T-cells will be administered inpatient as a single infusion of 1x10\^6 19-28z CAR T-cells/kg, for those in the B-ALL cohort, or 2x10\^6 19-28z CAR T-cells/kg, for those in the DLBCL cohort. Patients will be observed inpatient for a minimum of 7 days (longer as clinically indicated and at the discretion of the treating physician).
Study: NCT04726241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and/or bone marrow samples
Study: NCT06132152

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open hemorrhoidectomy with 'cold' scalpel
Description: Open hemorrhoidectomy will be performed in traditional way, including radial skin-mucosal excision of enlarged hemorrhoids with ligation of the vascular pedicle. 'Cold' scalpel will be used for cutting the perianal skin and anal mucose. To stop and prevent bleeding the monopolar coagulation may be used but on low energy level and with no touching the skin and mucose.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open hemorrhoidectomy with electrosurgical scalpel
Description: Open hemorrhoidectomy will be performed in traditional way, including radial skin-mucosal excision of enlarged hemorrhoids with ligation of the vascular pedicle. Electrosurgical scalpel will be used during all steps including cutting the perianal skin and anal mucose and to stop and prevent bleeding.
Study: NCT05813379

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: exosime injection
Description: Treatment- exosome injection
Study: NCT05947526

Intervention type: PROCEDURE
Intervention: Oocyte pick-up
Description: With the needle, transvaginally USG-guided oocyte pick-up procedure is going to be performed
Study: NCT05738655

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pumpkin seed extract (Low dose)
Description: Pumpkin seed extract standardized with specific peptides (300 mg/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pumpkin seed extract (High dose)
Description: Pumpkin seed extract standardized with specific peptides (600 mg/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placeo (300 mg/day)
Study: NCT04897191

Intervention type: OTHER
Intervention: Age
Description: Determination of age-dependence
Study: NCT05650268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Receiving 576000 international units in single oral dose of liquid vitamin D 3\~7 days prior to the surgery.
Study: NCT06433583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous auricular vagal nerve stimulation
Description: The use of TENS ECO PLUS and the vagus nerve ear electrode medical devices for transcutaneous auricular vagal nerve stimulation (taVNS) everyday for 10 minutes twice a day or 20 minutes for 8 successive weeks. Patients are included at week 0, use taVNS between week 2 and 10, and are followed up until week 22.~Patient adherence: percentage of patients performing 20 minutes of daily stimulation on at least 5 days a week for at least 6 cumulative weeks.
Study: NCT05650268

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 95% MCT
Description: 95% MCT supplement 3-7 day before surgery